Leukemia
Leukemia
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
34
Clinical Trials
Leukemia
Phase I/II
Active
nct/study# NA / AT148002
A Phase 1/2 Study Of Alx148 In Combination With Azacitidine In Patients With Higher Risk Mds
Learn More
Leukemia
NA
Accepting Patients
Leukemia
Phase I/II
Active
nct/study# NCT02103478 / ASTX727-01
A Phase 1-2 Pharmacokinetic Guided Dose-Escalation And Dose-Confirmation Study Of ASTX727, A Combination Of The Oral Cytidine Deaminase Inhibitor (Cdai) E7727 With Oral Decitabine In Subjects With Myelodysplastic Syndromes (MDS)
Learn More
Leukemia
Phase III
Active
nct/study# NA / CMX-DS-003
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dociparstat sodium in combination with standard chemotherapy for the treatment of ACTIVEly-diagnosed acute myeloid leukemia
Learn More
Leukemia
Phase I/II
Active
nct/study# NA / APTEVO
Phase 1-2 Study Of A Bispecific CD3xCD123 Antibody In Acute Myeloid Leukemia Patients
Learn More
Leukemia
Phase III
Active
nct/study# NA / GS-US-546-5857
Phase 3 Study To Evaluate The Safety And Efficacy Of Magrolimab In Combination With Azacitidine Versus Physician’s Choice Of Venetoclax In Combination With Azacitidine Or Intensive Chemotherapy In Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2)
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.